Journal article · 2026 · Open access
Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023)
Value in Health, 29(9), 1672–1682 · Published 24 June 2026 · DOI 10.1016/j.jval.2026.04.017
In brief
“Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023)” is a 2026 journal article by Courtney Levy and 6 co-authors, published in Value in Health. OpenAlex counts 0 citations as of 22 November 2026. It is open access under a CC BY licence: the full text is free to read at Value in Health.
- Citations
- 0
- References
- 12
- Authors
- 7
Abstract
OBJECTIVES: Inclusion of patient-reported outcome (PRO) data in Summaries of Product Characteristics (SmPCs) and package leaflets published by the European Medicines Agency (EMA) is critical to communicate patient-reported value of new medicines. This study aimed to identify key issues in the incorporation and interpretation of PROs in clinical trials that may hinder approval of PRO-related language in SmPCs/package leaflets. METHODS: Indications of new medicines recommended for approval by the EMA between 2020 and 2023 were identified. The Public Assessment Reports, SmPCs, and package leaflets were systematically reviewed. Information pertaining to inclusion of PROs in confirmatory trial(s) and PRO-related reviewer comments were extracted and categorized. RESULTS: Of 167 indications examined, 58 (35%) included PRO-related statements of treatment effect in the SmPC/package leaflet. Critical comments by EMA reviewers focused on study design and PRO data robustness, concerns about statistical analysis, data quality, and PRO measure appropriateness. Such critiques did not always lead to exclusion of PROs from the SmPC, particularly when PRO endpoints were multiplicity-controlled. PRO data collected in unblinded trials-sometimes unavoidable-were often deemed acceptable if multiplicity-controlled. CONCLUSIONS: Review findings emphasize that thoughtful selection of PRO measures, their implementation in trial protocol design, and appropriate statistical analysis planning can strengthen the credibility of PRO results in confirmatory trials, which is critical for supporting the approval of PRO-based value messaging. Insights generated may be used by marketing authorization applicants to support a favorable assessment of PRO data by the EMA.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Levy, C., Sauchelli, S., Abel, J. L., Wraight, M., Oberdhan, D., Doward, L. C., & Gnanasakthy, A. (2026). Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023). Value in Health, 29(9), 1672–1682. https://doi.org/10.1016/j.jval.2026.04.017
MLA 9
Levy, Courtney, et al. “Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023).” Value in Health, vol. 29, no. 9, 2026, pp. 1672–1682. https://doi.org/10.1016/j.jval.2026.04.017.
Chicago
Levy, Courtney, Sarah Sauchelli, Jessica L. Abel, Mia Wraight, Dorothee Oberdhan, Lynda C. Doward, and Ari Gnanasakthy. 2026. “Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023).” Value in Health 29 (9): 1672–1682. https://doi.org/10.1016/j.jval.2026.04.017.
Harvard
Levy, C. et al. (2026) ‘Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023)’, Value in Health, 29(9), pp. 1672–1682. doi:10.1016/j.jval.2026.04.017.
IEEE
C. Levy et al., “Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023),” Value in Health, vol. 29, no. 9, pp. 1672–1682, 2026, doi: 10.1016/j.jval.2026.04.017.
BibTeX
@article{levy2026critical,
title = {{Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023)}},
author = {Levy, Courtney and Sauchelli, Sarah and Abel, Jessica L. and Wraight, Mia and Oberdhan, Dorothee and Doward, Lynda C. and Gnanasakthy, Ari},
journal = {Value in Health},
year = {2026},
volume = {29},
number = {9},
pages = {1672--1682},
doi = {10.1016/j.jval.2026.04.017},
url = {https://doi.org/10.1016/j.jval.2026.04.017}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- patient-reported outcomes
- regulatory submissions
- European Medicines Agency
- Summary of Product Characteristics
- package leaflets
- confirmatory trials
- multiplicity control
- unblinding
Work with this paper
Most-cited papers in Economics, Econometrics and Finance
- Theory of the firm: Managerial behavior, agency costs and ownership structureMichael C. Jensen, William H. Meckling · Journal of Financial Economics · 1976 · 77,585 citations
- Institutions, Institutional Change and Economic PerformanceDouglass C. North · Cambridge University Press eBooks · 1990 · 34,377 citations
- The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.John E. Ware, Cathy Donald Sherbourne · PubMed · 1992 · 33,943 citations
- Some Tests of Specification for Panel Data: Monte Carlo Evidence and an Application to Employment EquationsManuel Arellano, Stephen R. Bond · The Review of Economic Studies · 1991 · 33,778 citations
- Co-Integration and Error Correction: Representation, Estimation, and TestingRobert F. Engle, C.W.J. Granger · Econometrica · 1987 · 32,847 citations
Questions about this paper
How do I cite this paper in APA style?
Levy, C., Sauchelli, S., Abel, J. L., Wraight, M., Oberdhan, D., Doward, L. C., & Gnanasakthy, A. (2026). Critical Comments by the European Medicines Agency on Patient-Reported Outcomes in Regulatory Submissions (2020 to 2023). Value in Health, 29(9), 1672–1682. https://doi.org/10.1016/j.jval.2026.04.017
How many times has this paper been cited?
0 times, according to OpenAlex on 22 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Value in Health: sign in and open the PDF from this page.
Who wrote this paper?
Courtney Levy, Sarah Sauchelli, Jessica L. Abel, Mia Wraight, Dorothee Oberdhan, Lynda C. Doward, Ari Gnanasakthy.
What is the DOI of this paper?
10.1016/j.jval.2026.04.017, permanently at https://doi.org/10.1016/j.jval.2026.04.017. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 22 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.